Concepedia
Statistics
Publications
5
Citations
194
H-Index
Active since
2017
Affiliations
Eli Lilly (United States)(Current)
Loxo Oncology at Lilly (United States)
Eli Lilly (Spain)
Lisa Kindler is an author at Eli Lilly (United States) specializing in oncology, pharmacology, and molecular oncology.
Publications per year
2017–2024
ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Shripad V. Bhagwat, William T. McMillen, Shufen Cai et al. · Molecular Cancer Therapeutics · 2019 · 108 citations · Full text
Medicine, Oncology, Pharmacology +17
Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)
Shripad V. Bhagwat, Baohui Zhao, Weihua Shen et al. · Cancer Research · 2021 · 31 citations
Abstract 4973: Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations
Shripad V. Bhagwat, William T. McMillen, Shufen Cai et al. · Cancer Research · 2017 · 22 citations
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Shripad V. Bhagwat, Cecilia Mur, Matthew Vandekopple et al. · Cancer Research · 2024 · 22 citations · Full text
Medicine, Oncology, Pharmacology +16
Abstract P142: Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor
Anke Klippel, Rui Wang, Loredana Puca et al. · Molecular Cancer Therapeutics · 2021 · 11 citations
1–5 of 5